S&P 500   3,279.93 (-0.91%)
DOW   26,463.07 (-0.74%)
QQQ   274.15 (-0.81%)
AAPL   110.74 (-3.97%)
MSFT   203.50 (-0.60%)
FB   272.50 (-2.97%)
GOOGL   1,666.29 (+7.03%)
AMZN   3,128.16 (-2.58%)
TSLA   403.21 (-1.85%)
NVDA   514.16 (-1.31%)
BABA   309.80 (-0.88%)
GE   7.39 (+0.27%)
MU   50.11 (-0.73%)
AMD   76.87 (-1.47%)
T   26.83 (+0.26%)
F   7.83 (-0.89%)
ACB   3.96 (-3.18%)
GILD   58.49 (-0.07%)
NIO   30.98 (-3.16%)
NFLX   503.73 (-0.10%)
BA   148.76 (+0.32%)
DIS   121.72 (+0.15%)
S&P 500   3,279.93 (-0.91%)
DOW   26,463.07 (-0.74%)
QQQ   274.15 (-0.81%)
AAPL   110.74 (-3.97%)
MSFT   203.50 (-0.60%)
FB   272.50 (-2.97%)
GOOGL   1,666.29 (+7.03%)
AMZN   3,128.16 (-2.58%)
TSLA   403.21 (-1.85%)
NVDA   514.16 (-1.31%)
BABA   309.80 (-0.88%)
GE   7.39 (+0.27%)
MU   50.11 (-0.73%)
AMD   76.87 (-1.47%)
T   26.83 (+0.26%)
F   7.83 (-0.89%)
ACB   3.96 (-3.18%)
GILD   58.49 (-0.07%)
NIO   30.98 (-3.16%)
NFLX   503.73 (-0.10%)
BA   148.76 (+0.32%)
DIS   121.72 (+0.15%)
S&P 500   3,279.93 (-0.91%)
DOW   26,463.07 (-0.74%)
QQQ   274.15 (-0.81%)
AAPL   110.74 (-3.97%)
MSFT   203.50 (-0.60%)
FB   272.50 (-2.97%)
GOOGL   1,666.29 (+7.03%)
AMZN   3,128.16 (-2.58%)
TSLA   403.21 (-1.85%)
NVDA   514.16 (-1.31%)
BABA   309.80 (-0.88%)
GE   7.39 (+0.27%)
MU   50.11 (-0.73%)
AMD   76.87 (-1.47%)
T   26.83 (+0.26%)
F   7.83 (-0.89%)
ACB   3.96 (-3.18%)
GILD   58.49 (-0.07%)
NIO   30.98 (-3.16%)
NFLX   503.73 (-0.10%)
BA   148.76 (+0.32%)
DIS   121.72 (+0.15%)
S&P 500   3,279.93 (-0.91%)
DOW   26,463.07 (-0.74%)
QQQ   274.15 (-0.81%)
AAPL   110.74 (-3.97%)
MSFT   203.50 (-0.60%)
FB   272.50 (-2.97%)
GOOGL   1,666.29 (+7.03%)
AMZN   3,128.16 (-2.58%)
TSLA   403.21 (-1.85%)
NVDA   514.16 (-1.31%)
BABA   309.80 (-0.88%)
GE   7.39 (+0.27%)
MU   50.11 (-0.73%)
AMD   76.87 (-1.47%)
T   26.83 (+0.26%)
F   7.83 (-0.89%)
ACB   3.96 (-3.18%)
GILD   58.49 (-0.07%)
NIO   30.98 (-3.16%)
NFLX   503.73 (-0.10%)
BA   148.76 (+0.32%)
DIS   121.72 (+0.15%)
Log in
NASDAQ:SESN

Sesen Bio Stock Forecast, Price & News

$1.06
-0.02 (-1.85 %)
(As of 10/30/2020 09:37 AM ET)
Add
Compare
Today's Range
$1.05
Now: $1.06
$1.06
50-Day Range
$1.00
MA: $1.21
$1.40
52-Week Range
$0.37
Now: $1.06
$1.54
Volume400 shs
Average Volume1.49 million shs
Market Capitalization$124.20 million
P/E RatioN/A
Dividend YieldN/A
Beta1.08
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate, which is in Phase I/II clinical trials for use in the treatment of various types of EpCAM-positive solid tumors. It is also developing Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor that is in Phase I/IIa clinical trials for the treatment of squamous cell carcinoma of the head and neck. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Read More
Sesen Bio logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.24 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SESN
CUSIPN/A
CIKN/A
Phone617-444-8550
Employees25

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$430,000.00
Book Value($0.26) per share

Profitability

Net Income$-107,500,000.00

Miscellaneous

Market Cap$124.20 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$1.06
-0.02 (-1.85 %)
(As of 10/30/2020 09:37 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SESN News and Ratings via Email

Sign-up to receive the latest news and ratings for SESN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sesen Bio (NASDAQ:SESN) Frequently Asked Questions

How has Sesen Bio's stock price been impacted by Coronavirus (COVID-19)?

Sesen Bio's stock was trading at $0.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SESN stock has increased by 50.0% and is now trading at $1.08.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Sesen Bio?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sesen Bio in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Sesen Bio
.

When is Sesen Bio's next earnings date?

Sesen Bio is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Sesen Bio
.

How were Sesen Bio's earnings last quarter?

Sesen Bio, Inc. (NASDAQ:SESN) posted its earnings results on Monday, August, 10th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.15.
View Sesen Bio's earnings history
.

What price target have analysts set for SESN?

2 equities research analysts have issued 12-month target prices for Sesen Bio's shares. Their forecasts range from $2.25 to $5.00. On average, they expect Sesen Bio's stock price to reach $3.63 in the next year. This suggests a possible upside of 235.6% from the stock's current price.
View analysts' price targets for Sesen Bio
.

Are investors shorting Sesen Bio?

Sesen Bio saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 1,810,000 shares, an increase of 13.8% from the September 30th total of 1,590,000 shares. Based on an average trading volume of 2,410,000 shares, the days-to-cover ratio is presently 0.8 days.
View Sesen Bio's Short Interest
.

Who are some of Sesen Bio's key competitors?

What other stocks do shareholders of Sesen Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sesen Bio investors own include Amarin (AMRN), XOMA (XOMA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Verastem (VSTM), Sorrento Therapeutics (SRNE), Novavax (NVAX), Biocept (BIOC), Micron Technology (MU) and Opko Health (OPK).

Who are Sesen Bio's key executives?

Sesen Bio's management team includes the following people:
  • Dr. Thomas R. Cannell, Pres, CEO & Director (Age 58, Pay $836k)
  • Ms. Monica Forbes, Chief Financial Officer (Age 44, Pay $371.34k)
  • Mr. Mark R. Sullivan, Gen. Counsel & Corp. Sec. (Age 49, Pay $813.39k)
  • Dr. Gregory L. Verdine, Co-Founder (Age 61)
  • Ms. Kirstin Nettelbladt Anderson, Corp. Controller & Principal Accounting Officer (Age 47)
  • Dr. Glen C. MacDonald, Chief Technology Officer (Age 69)
  • Ms. Erin Clark, VP of Corp. Strategy & Investor Relations
  • Dr. David Brooks, Sr. VP of Clinical Devel.
  • Dr. Dennis Kim M.D., MPH, Chief Medical Officer (Age 51)
  • Dr. Jeannick Cizeau, Head of Research

What is Sesen Bio's stock symbol?

Sesen Bio trades on the NASDAQ under the ticker symbol "SESN."

How do I buy shares of Sesen Bio?

Shares of SESN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sesen Bio's stock price today?

One share of SESN stock can currently be purchased for approximately $1.08.

How big of a company is Sesen Bio?

Sesen Bio has a market capitalization of $126.55 million and generates $430,000.00 in revenue each year. The company earns $-107,500,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Sesen Bio employs 25 workers across the globe.

What is Sesen Bio's official website?

The official website for Sesen Bio is www.sesenbio.com.

How can I contact Sesen Bio?

Sesen Bio's mailing address is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-444-8550 or via email at [email protected]

This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.